- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01550549
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
Study Overview
Status
Intervention / Treatment
Detailed Description
Avid has previously developed a florbetapir-PET scan binary read methodology and training program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369), 18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies, training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of this training program suitable for web-based distribution. Nuclear medicine physicians will complete the automated training program then read the florbetapir-PET images from 151 subjects with repeat readings of 33 randomly selected images. Readers will rate each case as either positive for significant tracer accumulation in cortical gray matter or negative for significant tracer accumulation in cortical gray matter. The inter-rater reliability, sensitivity and specificity of the readers will be evaluated.
The primary image set for determination of inter-reader agreement is comprised of images from 119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20 with mild cognitive impairment) MCI, 20 with AD.
Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients that were not used in the training program (n=32); 13 of these 32 scans presented for repeat reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased the number of unique cases in the validation dataset to 151 scans with 33 scans repeated yielding a total of 184 scans reviewed by the readers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligibility for subjects scans to be used in this study is determined by subject's eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).
Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- Have probable AD per National Institute of Neurological and Communication Disorders and Stroke (NINCDS) criteria
- Mini mental state exam (MMSE) score between 10 and 24 inclusive
Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):
- Male or female at least 50 years of age
- Complaints of memory or cognitive decline corroborated by an informant
- Clinical dementia rating of 0.5
- No obvious cause for cognitive impairment (eg, head trauma or stroke)
- Cognitive impairment onset within the past year
- MMSE score greater than 24
Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- MMSE score greater than or equal to 29 and cognitively normal by informant report and psychometric test battery at screening
Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):
- Male or female 18 years or older
- Projected life expectancy of less than 6 months
- Consent to brain donation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inter-rater Reliability
Time Frame: Scan acquired 50-60 min post-injection
|
Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa.
All scans were read in a blinded fashion without access to clinical information.
|
Scan acquired 50-60 min post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Time Frame: at autopsy, within 2 years of scan
|
Calculated as the percent of true positives which are correctly identified
|
at autopsy, within 2 years of scan
|
Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Time Frame: at autopsy, within 2 years of scan
|
Calculated as the percent of true negatives which are correctly identified
|
at autopsy, within 2 years of scan
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Sensitivity and Specificity vs. CERAD Diagnosis
Time Frame: Baseline scan
|
Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).
|
Baseline scan
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18F-AV-45-PT01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurodegenerative Diseases
-
University Hospital, Strasbourg, FranceRecruitingNeurodegenerative DisordersFrance
-
Fujian Medical University Union HospitalRecruitingNeurodegenerative DisordersChina
-
Imperial College LondonWithdrawn
-
First Affiliated Hospital of Fujian Medical UniversityRecruitingNeurodegenerative DisordersChina
-
University of PennsylvaniaAvid RadiopharmaceuticalsRecruiting
-
Fujian Medical University Union HospitalRecruitingNeurodegenerative DisorderChina
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseUnited States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
-
ACADIA Pharmaceuticals Inc.CompletedNeuropsychiatric Symptoms Related to Neurodegenerative DiseaseSerbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
-
National Institute of Neurological Disorders and...Completed
-
Istituto Auxologico ItalianoRecruitingNeurodegenerative DiseasesItaly
Clinical Trials on florbetapir F 18
-
Brigham and Women's HospitalTerminatedCardiac AmyloidosisUnited States
-
Avid RadiopharmaceuticalsWithdrawnAlzheimer's DiseaseJapan
-
Avid RadiopharmaceuticalsCompletedProgressive Cognitive DeclineUnited States
-
Avid RadiopharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedParkinson's DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's Disease
-
Avid RadiopharmaceuticalsCompletedMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
Avid RadiopharmaceuticalsCompletedAlzheimer's Disease
-
Avid RadiopharmaceuticalsCompletedAlzheimer's DiseaseUnited States
-
Avid RadiopharmaceuticalsCompleted